ProCE Banner Activity

Clinical Pearls With Gastroenteropancreatic NET Care

Clinical Thought

Experts discuss clinical pearls in the care of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Released: December 27, 2024

Expiration: December 26, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation

Novartis Pharmaceuticals Corporation

Disclosure

Primary Author

Thor R. Halfdanarson, MD

Consultant, Division of Medical Oncology
Professor of Oncology
Associate Professor of Medicine
Mayo Clinic Comprehensive Cancer Center
Chair, Hepato-Pancreatico-Biliary Disease Group
Rochester, Minnesota

Thor R. Halfdanarson, MD: researcher: Advances Accelerator Applications (a Novartis Company), Camurus, Crinetics, Exelixis, ITM, Perspective Therapeutics, TerSera, Thermo Fisher Scientific; consultant/advisor/speaker: Camurus, ITM, Novartis.

Jonathan Strosberg, MD

Professor, GI Oncology
Chair, Neuroendocrine Tumor Division
Moffitt Cancer Center and Research Institute
Tampa, Florida

Jonathan Strosberg, MD: consultant/advisor/speaker: Boehringer Ingelheim, Exelixis.